• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Tempus AI Inc.

    4/7/26 4:08:00 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology
    Get the next $TEM alert in real time by email
    DEFA14A 1 d129967ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.   )

     

     

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under § 240.14a-12

    TEMPUS AI, INC.

    (Name of Registrant as Specified in Its Charter)

    (Name of Person(s) Filing Proxy Statement if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     
     


    LOGO

    This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials Your Vote Counts! before voting. To view the Notice and Proxy Statement and Annual Report, and to obtain directions to attend the TEMPUS AI, INC. meeting, go to: www.ProxyVote.com. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be 2026 Annual Meeting of Stockholders distributed by making them available on the Internet. Vote by May 20, 2026 10:59 PM Central Time ATTN: LEGAL TEMPUS AI, INC. 600 WEST CHICAGO AVENUE, SUITE 510 CHICAGO, IL 60654 V90391-P46886 You invested in TEMPUS AI, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on May 21, 2026. Get informed before you vote View the Notice of Annual Meeting, Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 7, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Vote Virtually at the Meeting* Point your camera here and May 21, 2026 1:30 PM Central Time vote without entering a control number Virtually at: www.virtualshareholdermeeting.com/TEM2026 *Please check the meeting materials for any special requirements for meeting attendance.


    LOGO

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Voting Items Recommends 1. To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal. Nominees: 01) Eric Lefkofsky 06) Wayne A.I. Frederick, M.D. For 02) Peter J. Barris 07) Scott Gottlieb, M.D. 03) Eric D. Belcher 08) Theodore J. Leonsis 04) Jennifer A. Doudna 09) Nadja West, M.D. 05) David R. Epstein 2. To ratify the appointment by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the For Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. 3. To consider a non-binding advisory vote on the frequency of future stockholder votes to approve the compensation 3 Years of the Company’s named executive officers. NOTE: In their discretion, the proxyholders are authorized to vote upon such other business as may properly come before the meeting or any adjournment thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V90392-P46886

    Get the next $TEM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TEM

    DatePrice TargetRatingAnalyst
    2/19/2026$100.00Outperform
    Mizuho
    2/17/2026$59.00Outperform
    Robert W. Baird
    12/2/2025$85.00Overweight
    Morgan Stanley
    10/21/2025$88.00Buy → Hold
    TD Cowen
    10/20/2025$110.00Buy
    Canaccord Genuity
    9/2/2025$90.00Buy
    H.C. Wainwright
    4/21/2025$60.00Buy
    BTIG Research
    2/25/2025$50.00 → $55.00Overweight → Neutral
    Analyst
    More analyst ratings

    $TEM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho initiated coverage on Tempus AI with a new price target

    Mizuho initiated coverage of Tempus AI with a rating of Outperform and set a new price target of $100.00

    2/19/26 7:52:33 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Robert W. Baird initiated coverage on Tempus AI with a new price target

    Robert W. Baird initiated coverage of Tempus AI with a rating of Outperform and set a new price target of $59.00

    2/17/26 8:19:06 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Morgan Stanley resumed coverage on Tempus AI with a new price target

    Morgan Stanley resumed coverage of Tempus AI with a rating of Overweight and set a new price target of $85.00

    12/2/25 8:35:17 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    SEC Filings

    View All

    SEC Form DEFA14A filed by Tempus AI Inc.

    DEFA14A - Tempus AI, Inc. (0001717115) (Filer)

    4/7/26 4:08:00 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form DEF 14A filed by Tempus AI Inc.

    DEF 14A - Tempus AI, Inc. (0001717115) (Filer)

    4/7/26 4:06:20 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Tempus AI Inc.

    SCHEDULE 13G/A - Tempus AI, Inc. (0001717115) (Subject)

    3/27/26 1:32:45 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Lefkofsky Eric P

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    3/27/26 9:46:17 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Director Epstein David R sold $12,672 worth of shares (250 units at $50.69), decreasing direct ownership by 0.96% to 25,801 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    3/4/26 4:30:27 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Chief Financial Officer Rogers James William sold $578,576 worth of shares (11,414 units at $50.69), decreasing direct ownership by 8% to 127,248 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    3/4/26 4:30:25 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tempus and Medtronic Announce ALERT Trial Results Showing AI-Driven EHR Notifications Improve Treatment for Significant Valvular Heart Disease

    ALERT is the largest known multicenter, cluster-randomized trial to date evaluating an automated EHR-based notification system designed to address the undertreatment of significant valvular heart disease and accelerate time to treatment. Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from the ALERT (Addressing undertreatment and heaLth Equity in aortic stenosis and mitral regurgitation using an integrated ehR plaTform) trial, which were recently presented at the American College of Cardiology's 75th Annual Scientific Session & Expo. The study, conducted in collaboration with Medtronic, found that automat

    4/1/26 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Legendary Investors are Rotating Capital into AI Powered Biotech

    DENVER, March 30, 2026 (GLOBE NEWSWIRE) -- Cathie Wood and ARK Invest are making a decisive pivot that signals where the next phase of artificial intelligence value creation may emerge: healthcare. In a series of trades during late March, Wood aggressively reduced exposure to mega-cap technology and semiconductor names while building a high-conviction position in Tempus AI (NASDAQ:TEM). The move reflects a broader thesis she has increasingly emphasized, the most underestimated frontier for AI innovation is healthcare. As AI infrastructure becomes crowded and capital-intensive, ARK is rotating toward companies applying AI to real-world, high-stakes problems like disease detection, drug deve

    3/30/26 9:15:00 AM ET
    $CRSP
    $META
    $TEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Computer Software: Programming Data Processing
    Technology

    Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global nonprofit focused on blood cancer patient support, research, and advocacy, today announced a strategic collaboration to develop a comprehensive, patient-centered, real-world registry for pediatric acute myeloid leukemia (pAML), a rare and aggressive blood cancer. Part of the Blood Cancer United Dare to Dream Project, the collaboration serves a dual purpose: empowering patients with their health-related data and information relevant to their journey and fueling broader scientific breakthroughs.

    3/17/26 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tempus Ai, Inc. bought $2,739,181 worth of shares (320,267 units at $8.55), increasing direct ownership by 3% to 13,039,067 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Reporting)

    2/13/26 5:24:46 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Large owner Tempus Ai, Inc. exercised 9,218,800 in-the-money shares at a strike of $2.00 and bought $17,745,000 worth of shares (3,500,000 units at $5.07) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Reporting)

    8/20/24 4:17:55 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Financials

    Live finance-specific insights

    View All

    Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 4652845 United States - New York: (646) 307-1963 USA & Canada - Toll-Free: (800) 715-9871 Live Webcast: https://edge.media-

    2/10/26 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus to Report Third Quarter 2025 Financial Results on November 4

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on November 4, 2025. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 5436492 USA & Canada: Toll-Free (800) 715-9871 United States: Toll (646) 307-1963 Live Webcast: https://edge.media-server.com/mmc/p/vg3azega A

    10/21/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus Announces the Acquisition of Paige

    Paige's strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry leading technology portfolio. Founded in 2017, Paige has developed and deployed several AI applications, including the first FDA-cleared AI application in pathology, allowin

    8/22/25 9:20:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Leadership Updates

    Live Leadership Updates

    View All

    FDA Clearance Sets Stage for U.S. Commercialization of eyonis® LCS Software as a Medical Device for Lung Cancer Screening; Oran Muduroglu Appointed President of Median eyonis Inc.

    Oran Muduroglu, proven medical imaging entrepreneur, to lead U.S. launch of eyonis® LCS Established U.S. commercial and clinical infrastructure combined with Medicare reimbursement pathway already in place to support expansion Active discussions underway to establish key clinical partnerships to support broad access across U.S. lung cancer screening programs Webcasts will be held on February 26, 2026, to discuss the Company's recent achievements and upcoming milestones for eyonis® LCS deployment in the U.S. Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218440005/en/Oran Muduroglu Appointed Presi

    2/18/26 11:45:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The meeting is taking place November 5 - 9 at the Gaylord National Convention Center in National Harbor, Maryland. "We're excited to join the oncology community at this year's meeting and highlight our latest research and progress in advancing the immuno-oncology field," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "Our latest findings demonstrate the potential of integrated, data-driven approaches to refine biomarkers, im

    11/5/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tempus AI Inc.

    SC 13G - Tempus AI, Inc. (0001717115) (Subject)

    11/12/24 5:00:02 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13G filed by Tempus AI Inc.

    SC 13G - Tempus AI, Inc. (0001717115) (Subject)

    11/12/24 4:30:28 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13D/A filed by Tempus AI Inc.

    SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)

    8/20/24 4:27:51 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology